专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014137363A1 BIOIMPEDANCE CIRCUMFERENCE MEASUREMENT 审中-公开
标题翻译：生物循环测量
公开(公告)号：WO2014137363A1
公开(公告)日：2014-09-12
申请号：PCT/US2013/036921
申请日：2013-04-17
申请人： FRESENIUS MEDICAL CARE HOLDINGS, INC.
发明人： ZHU, Fansan , LEVIN, Nathan, W.
IPC分类号： A61B5/103
CPC分类号： A61B5/0537 , A61B5/6828 , A61B2560/0412
摘要： Apparatus is disclosed for measuring the circumference of a limb of an individual, e.g., the individual's arm and/or calf. The apparatus uses one or more magnetic strips which surround the limb and contain magnetic coding of length information. Tension is applied to the magnetic strip by a tensioning assembly, which can be a pressure cuff or a stepping motor, and a magnetic read head reads the magnetic coding of length information from the strip. When used in a bioimpedance analysis procedure, the length information can be used to convert measured voltage differences into normalized bioimpedance values, e.g., resistivity values.
摘要翻译：公开了用于测量个体的肢体的周长的装置，例如个体的手臂和/或小腿。该装置使用围绕肢体的一个或多个磁条并且包含长度信息的磁编码。通过张紧组件将张力施加到磁条上，张紧组件可以是压力袖带或步进电机，并且磁读头读取来自条带的长度信息的磁编码。当用于生物阻抗分析程序时，长度信息可用于将测量的电压差转换成归一化的生物阻抗值，例如电阻率值。

2. 发明申请

WO2012051261A2 DRY WEIGHT PREDICTOR 审中-公开
标题翻译：干重预测
公开(公告)号：WO2012051261A2
公开(公告)日：2012-04-19
申请号：PCT/US2011/055916
申请日：2011-10-12
申请人： FRESENIUS MEDICAL CARE HOLDINGS, INC. , LEVIN, Nathan, W. , ZHU, Fansan
发明人： LEVIN, Nathan, W. , ZHU, Fansan
IPC分类号： G06F19/10
CPC分类号： A61B5/0537 , A61B5/6828 , G06F19/3481
摘要： Methods and apparatus for predicting/estimating the dry weight of an individual, e.g., a patient undergoing dialysis treatment, are provided. The techniques employ a bioimpedance measurement (303) on the individual's calf (101) to obtain information regarding the extracellular fluid volume of the calf. Using a measurement of the calf's circumference (309), a resistivity value is calculated, normalized by the individual's body mass index (BMI), and then offset by a reference value to obtain a new variable, ΔnRho, which is shown, by comparison with a "gold standard" (FIGS. 5-9), to be highly effective in predicting/estimating dry weight (FIGS. 10-13 and 15-16). The techniques are easy to use and provide accurate dry weight predictions/estimations without substantially adding to the complexity or cost of dialysis procedures. The techniques can also be used for individuals who are not renal patients, e.g., patients suffering from other diseases in which fluid overload can occur, athletes, fitness enthusiasts, and the like.
摘要翻译：提供了用于预测/估计个体（例如正在进行透析治疗的患者）的干重的方法和设备。该技术在个体的小腿（101）上采用生物阻抗测量（303）来获得关于小腿的细胞外液体积的信息。使用小腿周长的测量（309），计算电阻率值，通过个体的身体质量指数（BMI）归一化，然后偏移参考值以获得新变量ΔnRho，通过与 “金标准” （图5-9）在预测/估计干重时非常有效（图10-13和15-16）。这些技术易于使用，并提供准确的干重预测/估算，而不会增加透析程序的复杂性或成本。该技术还可以用于不是肾病人的个体，例如患有可能发生体液过量的其他疾病的患者，运动员，健身爱好者等等。

3. 发明申请

WO2013043598A1 ESTIMATION OF THE DRY WEIGHT OF A DIALYSIS PATIENT 审中-公开
标题翻译： DIALYSIS患者干重的估计
公开(公告)号：WO2013043598A1
公开(公告)日：2013-03-28
申请号：PCT/US2012/055914
申请日：2012-09-18
申请人： FRESENIUS MEDICAL CARE HOLDINGS, INC. , FRESENIUS MEDICAL CARE DEUTSCHLAND, GMBH , LEVIN, Nathan, W. , ZHU, Fansan , KOTANKO, Peter , WABEL, Peter , TETTA, Ciro
发明人： LEVIN, Nathan, W. , ZHU, Fansan , KOTANKO, Peter , WABEL, Peter , TETTA, Ciro
IPC分类号： A61M1/14
CPC分类号： A61M1/1611 , A61B5/0205 , A61B5/021 , A61B5/0261 , A61B5/028 , A61B5/0295 , A61B5/0537 , A61B5/08 , A61B5/14546 , A61B5/1455 , A61B5/4839 , A61B5/4875 , A61B5/4878 , A61B6/50 , A61B8/0891 , A61B8/5223 , A61M1/16 , A61M2205/3303 , A61M2205/3317 , A61M2230/04 , A61M2230/20 , A61M2230/65
摘要： In an embodiment, the invention relates to methods, apparatus, computer programs and computer program products for estimating a dry weight of a dialysis patient comprising the steps of determining a first fluid status of the patient between treatment sessions in a first stage, determining a second fluid status of the patient during treatment sessions in a second stage and estimating the dry weight based on the second fluid status.
摘要翻译：在一个实施例中，本发明涉及用于估计透析患者的干重的方法，装置，计算机程序和计算机程序产品，包括以下步骤：在第一阶段中在治疗阶段之间确定患者的第一流体状态，确定第二阶段在第二阶段的治疗期间患者的流体状态，并且基于第二流体状态估计干重。

4. 发明申请

WO2011133869A1 SYSTEM AND METHOD OF IDENTIFYING WHEN A PATIENT UNDERGOING HEMODIALYSIS IS AT INCREASED RISK OF DEATH BY A LOGISTIC REGRESSION MODEL 审中-公开
标题翻译：当病人出现HEMODIALYSIS时，通过物流回归模型导致死亡风险升高的系统和方法
公开(公告)号：WO2011133869A1
公开(公告)日：2011-10-27
申请号：PCT/US2011/033590
申请日：2011-04-22
申请人： FRESENIUS MEDICAL CARE HOLDINGS, INC. , KOTANKO, Peter , THIJSSEN, Stephan , USVYAT, Len , LEVIN, Nathan, W.
发明人： KOTANKO, Peter , THIJSSEN, Stephan , USVYAT, Len , LEVIN, Nathan, W.
IPC分类号： G06F19/00
CPC分类号： G16H50/70 , G06F19/00
摘要： Identifying a patient undergoing periodic hemodialysis treatments at increased risk of death by a logistic regression model includes selecting one or more clinical or biochemical parameter parameters associated with a probability of death of the patient while the patient is undergoing periodic hemodialysis treatments, and estimating the probability of death of the patient over a future time interval by a logistic regression model including model coefficients, the model coefficients determined by analyzing data from deceased patients that were previously undergoing periodic hemodialysis treatments, the analysis including a longitudinal analysis backwards in time on the one or more clinical or biochemical parameters of the deceased patients. The patient is identified as having an increased risk of death if the probability of death of the patient is greater than a predetermined threshold probability.
摘要翻译：识别通过逻辑回归模型进行定期血液透析治疗的死亡风险增加的患者包括在患者进行定期血液透析治疗时选择与患者的死亡概率相关联的一个或多个临床或生物化学参数参数，并且估计通过包括模型系数在内的逻辑回归模型，通过分析以前进行定期血液透析治疗的死亡患者的数据确定的模型系数，患者在未来时间间隔中的死亡，该分析包括在一个或多个时间上向后退的纵向分析死亡患者的临床或生物化学参数。如果患者的死亡概率大于预定的阈值概率，则患者被鉴定为具有增加的死亡风险。

5. 发明申请

WO2013036836A3 SYSTEM AND METHOD OF MODELING ERYTHROPOIESIS AND ITS MANAGEMENT 审中-公开
公开(公告)号：WO2013036836A3
公开(公告)日：2013-03-14
申请号：PCT/US2012/054264
申请日：2012-09-07
申请人： FRESENIUS MEDICAL CARE HOLDINGS, INC. , FUERTINGER, Doris, Helene , KAPPEL, Franz , KOTANKO, Peter , LEVIN, Nathan, W. , THIJSSEN, Stephan
发明人： FUERTINGER, Doris, Helene , KAPPEL, Franz , KOTANKO, Peter , LEVIN, Nathan, W. , THIJSSEN, Stephan
IPC分类号： G06F19/00
摘要： A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, and employing the patient parameters and an initially selected EPO administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen. Optionally, if the patient's hematocrit and/or hemoglobin concentration is not predicted by the model to be in the desired range at the predetermined time, the method includes employing the model with one or more different ESA administration regimens until the model predicts that the patient's hematocrit and/or hemoglobin concentration will be in the desired range at the predetermined time. The method then includes administering ESA to the patient with an ESA administration regimen predicted to adjust the patient's hematocrit and/or hemoglobin concentration to the desired range at the predetermined time. The method can be implemented in a computer system for adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen.

6. 发明申请

WO2010045558A1 METHOD OF DETERMINING A PHOSPHORUS BINDER DOSAGE FOR A DIALYSIS PATIENT 审中-公开
标题翻译：确定溶解患者的磷酸盐剂量的方法
公开(公告)号：WO2010045558A1
公开(公告)日：2010-04-22
申请号：PCT/US2009/061009
申请日：2009-10-16
申请人： FRESENIUS MEDICAL CARE HOLDINGS, INC. , GOTCH, Frank, A. , LIPPS, Benjamin, J. , KOTANKO, Peter , LEVIN, Nathan, W. , STENNETT, Amanda, K. , OFSTHUN, Norma, J.
发明人： GOTCH, Frank, A. , LIPPS, Benjamin, J. , KOTANKO, Peter , LEVIN, Nathan, W. , STENNETT, Amanda, K. , OFSTHUN, Norma, J.
IPC分类号： A61K31/00 , A61K31/785 , A61K33/06 , A61K45/06 , A61P3/12 , A61P3/14 , A61P13/12 , A61P35/00 , G01N33/84
CPC分类号： A61K31/785 , A61K31/00 , A61K33/06 , A61K45/06 , G01N33/84 , A61K2300/00
摘要： The invention is directed to a method of determining a dosage of phosphorus binder for a patient undergoing dialysis treatment to achieve a pre-dialysis serum phosphorus concentration within a desired concentration range while achieving a desired net accumulation of calcium. The method includes determining the dosage of phosphorus binder that will achieve pre-dialysis serum phosphorus concentration of the patient that is within the desired concentration range while accounting for the change in the amount of phosphorus removed by the dialysis treatment when the pre-dialysis serum phosphorus concentration of the patient is within the desired concentration range, determining a dialysate calcium concentration that will result in the desired net accumulation of calcium over a complete dialysis cycle, and dialyzing the patient with a dialysate containing a calcium concentration based upon that determination.
摘要翻译：本发明涉及一种确定用于经历透析治疗的患者的磷粘合剂的剂量的方法，以在实现期望的钙积累的情况下在期望的浓度范围内实现透析前血清磷浓度。该方法包括测定磷粘合剂的剂量，其将达到所需浓度范围内患者的透析前血清磷浓度，同时考虑透析治疗时去除的磷的量的变化，当透析前血清磷患者的浓度在所需的浓度范围内，确定透析液钙浓度，其将导致在完全透析循环中钙的期望的净积聚，并且使用含有基于该测定的钙浓度的透析液透析患者。

7. 发明申请

WO2010045474A2 METHOD OF REMOVING PROTEIN-BOUND DELETERIOUS SUBSTANCES DURING EXTRACORPOREAL RENAL REPLACEMENT TREATMENT 审中-公开
标题翻译：在超声内膜替代治疗期间移除蛋白质结合的去除物质的方法
公开(公告)号：WO2010045474A2
公开(公告)日：2010-04-22
申请号：PCT/US2009/060870
申请日：2009-10-15
申请人： FRESENIUS MEDICAL CARE HOLDINGS, INC. , KOTANKO, Peter , LEVIN, Nathan, W.
发明人： KOTANKO, Peter , LEVIN, Nathan, W.
IPC分类号： A61M1/36
CPC分类号： A61M1/16 , A61M1/3431 , A61M1/3458 , A61M1/3679 , A61M1/3687

8. 发明申请

WO2014035947A1 DETECTING INDICATIONS OF INTRADIALYTIC MORBID EVENTS BY MEASUREMENT OF RELATIVE BLOOD VOLUME, BLOOD PRESSURE AND HEART RATE 审中-公开
标题翻译：通过测量相对血液体积，血压和心率来检测干细胞因子活动的适应症
公开(公告)号：WO2014035947A1
公开(公告)日：2014-03-06
申请号：PCT/US2013/056769
申请日：2013-08-27
申请人： FRESENIUS MEDICAL CARE HOLDINGS, INC.
发明人： ZHU, Fansan , KOTANKO, Peter , THIJSSEN, Stephan , LEVIN, Nathan, W.
IPC分类号： A61B5/02
CPC分类号： A61B5/746 , A61B5/021 , A61M1/16 , A61M1/1603 , A61M1/1615 , A61M1/341 , A61M1/3413 , A61M1/3609 , A61M2230/06 , A61M2230/30
摘要： A method of detecting an indication of a potential intradialytic morbid event (IME) by monitoring a patient's condition during excess fluid removal by ultrafiltration during a hemodialysis treatment includes determining the patient's relative blood volume (RBV), and removing a portion of the volume of excess fluid from blood of the patient at an initial ultrafiltration rate while periodically monitoring a second derivative over time of the relative blood volume (SDRBV). The method then includes continuing to remove excess fluid from blood of the patient at the same ultrafiltration rate, or, optionally, incrementally increasing the ultrafiltration rate. The method further includes triggering an alarm for an IME for the patient if the SDRBV is in a range of between a low SDRBV alarm level and a high SDRBV alarm level, and, alternatively or additionally monitoring the patient's normalized blood pressure ratio, and taking a remedial action if the alarm is triggered.
摘要翻译：通过在血液透析治疗期间通过超滤过量流体去除过程中监测患者的状况来检测潜在的体内病态事件（IME）的指示的方法包括确定患者的相对血容量（RBV），以及去除部分过量体积以最初的超滤速率从患者的血液中流出液体，同时周期性地监测相对血液体积（SDRBV）随时间变化的二次导数。然后该方法包括以相同的超滤速率继续从患者血液中除去多余的液体，或者任选地递增地提高超滤速率。该方法还包括如果SDRBV在低SDRBV警报水平和高SDRBV警报水平之间的范围内，触发针对患者的IME的警报，或者或另外监视患者的标准化血压比，并且如果报警被触发则补救措施。

9. 发明申请

WO2013185080A1 SYSTEM AND METHOD OF MONITORING AND CONTROL OF ULTRAFILTRATION VOLUME DURING PERITONEAL DIALYSIS USING SEGMENTAL BIOIMPEDANCE 审中-公开
标题翻译：使用分段生物利用方法进行腹膜透析期间超声量的监测和控制方法
公开(公告)号：WO2013185080A1
公开(公告)日：2013-12-12
申请号：PCT/US2013/044795
申请日：2013-06-07
申请人： FRESENIUS MEDICAL CARE HOLDINGS, INC.
发明人： ZHU, Fansan , LEVIN, Nathan, W.
IPC分类号： A61B5/1455 , A61B5/00 , A61B5/05 , A61B6/00 , A61M1/14 , A61M1/28 , A61M5/142 , G01N21/35
CPC分类号： A61M1/28 , A61B5/1451 , A61B5/4848 , A61B5/6866 , A61M1/281 , A61M1/282 , A61M1/284 , A61M2205/17 , A61M2205/18 , A61M2205/3317 , A61M2205/3344 , A61M2205/3379 , A61M2205/3569 , A61M2205/3592 , A61M2210/1017 , A61M2230/005
摘要： A peritoneal dialysis (PD) system for infusing a volume of PD solution into a patient's peritoneal cavity in order to perform peritoneal dialysis on the patient includes a peritoneal cavity monitor (PCM) that measures this volume of fluid in the patient's peritoneal cavity by segmental bioimpedance spectroscopy (SBIS), to thereby determine an ultrafiltration volume of fluid in the patient's peritoneal cavity, and a switch, controlled by the PCM, for filling the patient's peritoneal cavity and draining the patient's peritoneal cavity when the ultrafiltration volume is unchanged over time, significantly decreased, or decreasing at a significant rate.
摘要翻译：腹膜透析（PD）系统，用于将一定体积的PD溶液注入到患者的腹膜腔中以便对患者进行腹膜透析包括腹膜腔监测器（PCM），其通过分段生物阻抗来测量患者腹膜腔内的这种体积的流体光谱学（SBIS），从而确定患者腹膜腔中的液体的超滤体积，以及由PCM控制的开关，用于当超滤体积随时间不变而填充患者的腹膜腔并排出患者的腹膜腔减少或显着降低。

10. 发明申请

WO2012075222A2 METHOD OF IDENTIFYING WHEN A PATIENT UNDERGOING HEMODIALYSIS IS AT INCREASED RISK OF DEATH 审中-公开
标题翻译：当患者感染HEMODIALYSIS时死亡风险增加时，鉴定方法
公开(公告)号：WO2012075222A2
公开(公告)日：2012-06-07
申请号：PCT/US2011/062774
申请日：2011-12-01
申请人： FRESENIUS MEDICAL CARE HOLDINGS, INC. , KOTANKO, Peter , THIJSSEN, Stephan , USVYAT, Len , LEVIN, Nathan, W.
发明人： KOTANKO, Peter , THIJSSEN, Stephan , USVYAT, Len , LEVIN, Nathan, W.
IPC分类号： G01N33/53
CPC分类号： G01N33/5091 , G01N33/6893 , G01N2800/347 , G01N2800/56 , G06F19/00 , Y10T436/147777 , Y10T436/166666
摘要： The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin- Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.
摘要翻译：本发明涉及一种识别接受定期血液透析治疗的患者的方法，所述患者具有增加的死亡风险，其包括确定患者的临床或生物化学参数中的至少一个，其包括血清碳酸氢盐浓度水平，血清钾浓度水平，血清钙浓度水平，血红蛋白浓度水平，血清磷浓度水平，嗜中性粒细胞与淋巴细胞比值，平衡标准化蛋白分解代谢率（enPCR），通过透析和残留肾功能平衡的全身水分数（eKdrt / V），EPO抗性指数，转铁蛋白饱和指数，血清铁蛋白浓度水平，血清肌酸酐浓度水平，血小板计数，Aspartat-氨基转移酶水平和Alanin-氨基转移酶水平的定期血液透析治疗，并确定患者具有增加的死亡风险，如果患者的比率有显着变化的变化至少患者的临床或生物化学参数之一。本发明还涉及一种识别进行定期血液透析治疗的患者的死亡危险因素增加的方法。该方法包括分析先前正在进行定期血液透析治疗的死亡患者的数据，通过在患者的临床或生物化学参数变化的时间内向后进行纵向分析，并确定患者的下降率或增加率的显着变化患者死亡前的临床或生物化学参数。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式